During a 52-week extension period , subjects were up-titrated from 1 mg pitavastatin to a maximum dose of 4 mg in an effort to achieve an optimum low-density lipoprotein cholesterol ( LDL-C ) treatment target of < 110 mg/dL ( 2.8 mmol/L ) .